FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|August 10, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 10, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of August 3, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 32%
• Aged ≥65 years 39.1%
Fully vaccinated plus 1 booster dose:
• Total US population 48.2%
Fully vaccinated in key age groups:
• Total US population 67.2%
• Aged ≥5 years 71.4%
• Aged ≥65 years 91.8%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of August 10, 2022 at 5:20 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 458 528
• Texas 321 939
• Florida 281 850
• Total US confirmed cases 92 536 415
• Total US confirmed deaths 1 035 396
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 587 190 182
• Deaths 6 426 680 • Vaccine doses administered 12 010 588 528
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Advertisement
Advertisement
Trending on Patient Care Online
1
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
Unmet Needs and Mechanisms Behind Newer Agitation Therapies
4
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
5